WealthTrust Axiom’s Catheter Precision VTAK Stock Holding History

WealthTrust Axiom’s Portfolio VTAK Stock Details VTAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-35	Closed	-$39K	–	259
2022 Q3	$39K	Buy	+35	New	+$66.6K	0.01%	233

Other funds holding VTAK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

WealthTrust Axiom's VTAK Position: Q4 2022 in Review

WealthTrust Axiom sold out of Catheter Precision (VTAK) in Q4 2022, closing a stake of 35 shares — an estimated $39K sold.

WealthTrust Axiom first reported a position in VTAK in Q3 2022 and held it in 1 quarter. The position peaked at $39K in Q3 2022. 9 funds tracked by Wall St. Rank hold VTAK as of Q4 2022.

WealthTrust Axiom reported no remaining Catheter Precision position as of Q4 2022 after selling out during the quarter.
WealthTrust Axiom sold 35 Catheter Precision shares in Q4 2022, an estimated $39K.
WealthTrust Axiom first reported a position in Catheter Precision in Q3 2022 and held it in 1 quarter.
WealthTrust Axiom's Catheter Precision position peaked at $39K in Q3 2022.
9 funds tracked by Wall St. Rank held Catheter Precision as of Q4 2022.

Based on WealthTrust Axiom's 13F filing for Q4 2022, filed 31 Jan 2023.